U.S. Acute Respiratory Distress Syndrome (ARDS) Market - Industry Trends and Forecast to 2029

U.S. acute respiratory distress syndrome (ARDS) market is projected to register a CAGR of 10.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029
 

Market Segmentation: 
U.S. acute respiratory distress syndrome (ARDS) market, By Cause (Coronavirus Disease 2019 (COVID-19), Sepsis, Inhalation of Harmful Substances, Severe Pneumonia and Others), Type (Diagnosis and Treatment), Route of Administration (Parenteral Oral and Others), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Industry Trends and Forecast to 2029

Some of the major factors for the market growth are:

• Increasing prevalence and incidence of acute lung injury

• Acceleration in a patient pool of COVID-19 with ARDS

Market Players:

The key market players in U.S. acute respiratory distress syndrome (ARDS) market are listed below:

• Gilead Sciences, Inc.
• Terumo Medical Corporation
• Getinge AB.
• Medtronic
• LivaNova PLC
• Fresenius SE & Co. KGaA
• Drägerwerk AG & Co. KGaA
• F. Hoffmann-La Roche Ltd
• Fisher & Paykel Healthcare Limited.
• Hamilton Medical
• NIPRO
• Pfizer Inc.
• ResMed
• Smiths Medical
• WEINMANN Emergency Medical Technology GmbH + Co. KG